Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Sigma Healthcare Limited
ABN	15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Damien Gance
Date of last notice	12 February 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect

⁺ See chapter 19 for defined terms.

Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	DGSR Family Foundation Pty Ltd as trustee for the D Gance and S Robertson Family Foundation Trust (Damien Gance is the sole director and sole shareholder of DGSR Family Foundation Pty Ltd)
	Rispin & Mott Nominees Pty Ltd as bare trustee for Entourage Agency Pty Ltd as trustee for Entourage Agency Trust (DGSR Family Foundation Pty Ltd as trustee for the D Gance and S Roberston Family Foundation Trust is a unitholder of Entourage Agency Trust and Damien Gance is the sole director and sole shareholder of DGSR Family Foundation Pty Ltd)
	Rispin & Mott Nominees Pty Ltd as bare trustee for the DGSR Family Foundation Pty Ltd as trustee for the D Gance and S Roberston Family Foundation Trust (Damien Gance is the sole director and sole shareholder of DGSR Family Foundation Pty Ltd)
Date of change	14 February 2025
No. of securities held prior to change	DGSR Family Foundation Pty Ltd as trustee for the D Gance and S Robertson Family Foundation Trust: 393,829,615 ordinary shares
	Rispin & Mott Nominees Pty Ltd as bare trustee for Entourage Agency Pty Ltd as trustee for Entourage Agency Trust: 4,398,764 ordinary shares
	Rispin & Mott Nominees Pty Ltd as bare trustee for the DGSR Family Foundation Pty Ltd as trustee for the D Gance and S Roberston Family Foundation Trust: 2,011,644 ordinary shares
Class	Fully paid ordinary shares
Number acquired	N/A
Number disposed	40,000,000 ordinary shares

⁺ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	A\$120,000,000 (A\$3.00 per ordinary share)
No. of securities held after change	DGSR Family Foundation Pty Ltd as trustee for the D Gance and S Robertson Family Foundation Trust: 353,829,615 ordinary shares
	Rispin & Mott Nominees Pty Ltd as bare trustee for Entourage Agency Pty Ltd as trustee for Entourage Agency Trust: 4,398,764 ordinary shares
	Rispin & Mott Nominees Pty Ltd as bare trustee for the DGSR Family Foundation Pty Ltd as trustee for the D Gance and S Roberston Family Foundation Trust: 2,011,644 ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off-market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	

⁺ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – *Closed period

Were the interests in the securities	Yes, however see Sigma's ASX announcement of a
or contracts detailed above traded	Special Dispensation Period dated 12 February 2025
during a ⁺ closed period where prior	https://investorcentre.sigmahealthcare.com.au/static-
written clearance was required?	files/db7ea038-9c8e-4fc0-aa9a-e4c51ec72f95
If so, was prior written clearance	
provided to allow the trade to	
proceed during this period?	
If prior written clearance was	
provided, on what date was this provided?	

Appendix 3Y Page 4 01/01/2011

⁺ See chapter 19 for defined terms.